Page 13 - Read Online

Zhang et al. J Transl Genet Genom 2024;8:302-11 https://dx.doi.org/10.20517/jtgg.2024.39 Page 310

15. Fogo AB, Bostad L, Svarstad E, et al; all members of the International Study Group of Fabry Nephropathy (ISGFN). Scoring system
for renal pathology in Fabry disease: report of the International Study Group of Fabry Nephropathy (ISGFN). Nephrol Dial Transplant
2010;25:2168-77. DOI PubMed PMC
16. Tøndel C, Bostad L, Larsen KK, et al. Agalsidase benefits renal histology in young patients with Fabry disease. J Am Soc Nephrol
2013;24:137-48. DOI PubMed PMC
17. Valbuena C, Carvalho E, Bustorff M, et al. Kidney biopsy findings in heterozygous Fabry disease females with early nephropathy.
Virchows Arch 2008;453:329-38. DOI
18. Najafian B, Tøndel C, Svarstad E, Gubler MC, Oliveira JP, Mauer M. Accumulation of globotriaosylceramide in podocytes in Fabry
nephropathy is associated with progressive podocyte loss. J Am Soc Nephrol 2020;31:865-75. DOI PubMed PMC
19. Trimarchi H, Canzonieri R, Costales-Collaguazo C, et al. Early decrease in the podocalyxin to synaptopodin ratio in urinary Fabry
podocytes. Clin Kidney J 2019;12:53-60. DOI PubMed PMC
20. Nikolaenko V, Warnock DG, Mills K, Heywood WE. Elucidating the toxic effect and disease mechanisms associated with Lyso-Gb3
in Fabry disease. Hum Mol Genet 2023;32:2464-72. DOI PubMed PMC
21. Matafora V, Cuccurullo M, Beneduci A, et al. Early markers of Fabry disease revealed by proteomics. Mol Biosyst 2015;11:1543-51.
DOI
22. Trimarchi H, Ortiz A, Sánchez-Niño MD. Lyso-Gb3 increases αvβ3 integrin gene expression in cultured human podocytes in Fabry
nephropathy. J Clin Med 2020;9:3659. DOI PubMed PMC
23. Braun F, Abed A, Sellung D, et al. Accumulation of α-synuclein mediates podocyte injury in Fabry nephropathy. J Clin Invest
2023;133:e157782. DOI
24. Zarate YA, Hopkin DRJ. Fabry’s disease. Lancet 2008;372:1427-35. DOI PubMed
25. El Dib R, Gomaa H, Carvalho RP, et al. Enzyme replacement therapy for anderson-Fabry disease. Cochrane Database Syst Rev
2016;7:CD006663. DOI PubMed PMC
26. Cybulla M, Nicholls K, Feriozzi S, et al; FOS Study Group. Renoprotective effect of agalsidase alfa: a long-term follow-up of patients
with Fabry disease. J Clin Med 2022;11:4810. DOI PubMed PMC
27. Beck M, Ramaswami U, Hernberg-Ståhl E, et al. Twenty years of the Fabry outcome survey (FOS): insights, achievements, and
lessons learned from a global patient registry. Orphanet J Rare Dis 2022;17:238. DOI PubMed PMC
28. Tøndel C, Thurberg BL, DasMahapatra P, et al. Clinical relevance of globotriaosylceramide accumulation in Fabry disease and the
effect of agalsidase beta in affected tissues. Mol Genet Metab 2022;137:328-41. DOI
29. Nowak A, Dormond O, Monzambani V, Huynh-Do U, Barbey F. Agalsidase-β should be proposed as first line therapy in classic male
Fabry patients with undetectable α-galactosidase A activity. Mol Genet Metab 2022;137:173-8. DOI PubMed
30. Arends M, Biegstraaten M, Wanner C, et al. Agalsidase alfa versus agalsidase beta for the treatment of Fabry disease: an international
cohort study. J Med Genet 2018;55:351-8. DOI PubMed PMC
31. Weidemann F, Jovanovic A, Herrmann K, Vardarli I. Chaperone therapy in Fabry disease. Int J Mol Sci 2022;23:1887. DOI PubMed
PMC
32. Yam GH, Zuber C, Roth J. A synthetic chaperone corrects the trafficking defect and disease phenotype in a protein misfolding
disorder. FASEB J 2005;19:12-8. DOI
33. Müntze J, Gensler D, Maniuc O, et al. Oral chaperone therapy migalastat for treating Fabry disease: enzymatic response and serum
biomarker changes after 1 year. Clin Pharmacol Ther 2019;105:1224-33. DOI PubMed PMC
34. Coutinho MF, Santos JI, Alves S. Less is more: substrate reduction therapy for lysosomal storage disorders. Int J Mol Sci
2016;17:1065. DOI
35. Schiffmann R, Goker-Alpan O, Holida M, et al. Pegunigalsidase alfa, a novel PEGylated enzyme replacement therapy for Fabry
disease, provides sustained plasma concentrations and favorable pharmacodynamics: a-year phase 1/2 clinical trial. J Inherit Metab Dis
2019;42:534-44. DOI
36. Domm JM, Wootton SK, Medin JA, West ML. Gene therapy for Fabry disease: progress, challenges, and outlooks on gene-editing.
Mol Genet Metab 2021;134:117-31. DOI
37. Song HY, Chiang HC, Tseng WL, et al. Using CRISPR/Cas9-mediated GLA gene knockout as an in vitro drug screening model for
Fabry disease. Int J Mol Sci 2016;17:2089. DOI PubMed PMC
38. Germain DP. Reconceptualizing podocyte damage in Fabry disease: new findings identify α-synuclein as a putative therapeutic target.
Kidney Int 2024;105:237-9. DOI PubMed
39. Liebau MC, Braun F, Höpker K, et al. Dysregulated autophagy contributes to podocyte damage in Fabry’s disease. PLoS One
2013;8:e63506. DOI PubMed PMC
40. Li P, Xi Y, Zhang Y, et al. GLA mutations suppress autophagy and stimulate lysosome generation in Fabry disease. Cells 2024;13:437.
DOI PubMed PMC
41. Tuttolomondo A, Simonetta I, Riolo R, et al. Pathogenesis and molecular mechanisms of Anderson-Fabry disease and possible new
molecular addressed therapeutic strategies. Int J Mol Sci 2021;22:10088. DOI PubMed PMC
42. Warnock DG, Ortiz A, Mauer M, et al; Fabry Registry. Renal outcomes of agalsidase beta treatment for Fabry disease: role of
proteinuria and timing of treatment initiation. Nephrol Dial Transplant 2012;27:1042-9. DOI PubMed PMC
43. Warnock DG, Thomas CP, Vujkovac B, et al. Antiproteinuric therapy and Fabry nephropathy: factors associated with preserved
kidney function during agalsidase-beta therapy. J Med Genet 2015;52:860-6. DOI PubMed PMC